The importance of biobank and nationwide registry for lymphangioleiomyomatosis in a small sized country

Bibliography

• SGupta, AMBayoumi, MEFaughnan. Rare lung disease research: strategies for improving identification and recruitment of research participants. Chest 2011;140(5):1123-9
   PubMedGoogle Scholar
• CBForrest, RJBartek, YRubinstein, SCGroft. The case for a global rare-diseases registry. Lancet 2011;377(9771):1057-9
   PubMedGoogle Scholar
• SCGroft. Rare diseases research: expanding collaborative translational research opportunities. Chest 2013;144(1):16
   PubMedGoogle Scholar
• JHRyu, JMoss, GJBeck, et al. The NHLBI lymphangioleiomyomatosis registry: characteristics of 230 patients at enrollment. Am J Respir Crit Care Med 2006;173(1):105-11
   PubMed Web of Science ®Google Scholar
• EAntón, ACasanova, AXaubet, et al. Lymphangioleiomyomatosis: a study of 72 patients from the spanish registry. Sarcoidosis Vasc Diffuse Lung Dis 2009;26(2):85-91
   PubMedGoogle Scholar
• SPPorten, MRCooperberg, BRKonety, PRCarroll. The example of CaPSURE: lessons learned from a national disease registry. World J Urol 2011;29(3):265-71
   PubMed Web of Science ®Google Scholar
• FXMcCormack. Lymphangioleiomyomatosis*: a clinical update. Chest 2008;133(2):507-16
   PubMedGoogle Scholar
• RMeraj, KAWikenheiser-Brokamp, LRYoung, FXMcCormack. Lymphangioleiomyomatosis: new concepts in pathogenesis, diagnosis, and treatment. Semin Respir Crit Care Med 2012;33(5):486-97
   PubMedGoogle Scholar
• SHarari, OTorre, JMoss. Lymphangioleiomyomatosis: what do we know and what are we looking for? Eur Respir Rev 2011;20(119):34-44
   PubMedGoogle Scholar
• DWHohman, DNoghrehkar, SRatnayake. Lymphangioleiomyomatosis: a review. Eur J Intern Med 2008;19(5):319-24
   PubMedGoogle Scholar
• SRJohnson, JFCordier, RLazor, et al. European respiratory society guidelines for the diagnosis and management of lymphangioleiomyomatosis. Eur Respir J 2010;35(1):14-26
   PubMed Web of Science ®Google Scholar
• EPHenske, FXMcCormack. Lymphangioleiomyomatosis - a wolf in sheep’s clothing. J Clin Invest 2012;122(11):3807-16
   PubMed Web of Science ®Google Scholar
• NOprescu, FXMcCormack, SByrnes, BWKinder. Clinical predictors of mortality and cause of death in lymphangioleiomyomatosis: a population-based registry Lung. 2013;191(1):35-42
   Google Scholar
• MMavroudi, PZarogoulidis, NKatsikogiannis, et al. Lymphangioleiomyomatosis: current and future. J Thorac Dis 2013;5(1):74-9
   PubMed Web of Science ®Google Scholar
• RMeraj, KAWikenheiser-Brokamp, LRYoung, et al. Utility of transbronchial biopsy in the diagnosis of lymphangioleiomyomatosis. Front Med 2012;6(4):395-405
   PubMedGoogle Scholar
• LRYoung, RVandyke, PMGulleman, et al. Serum vascular endothelial growth factor-D prospectively distinguishes lymphangioleiomyomatosis from other diseases. Chest 2010;138(3):674-81
   PubMed Web of Science ®Google Scholar
• CJCudzilo, RDSzczesniak, ASBrody, et al. Lymphangioleiomyomatosis screening in women with tuberous sclerosis. Chest 2013;144(2):578-85
   PubMed Web of Science ®Google Scholar
• IGrzegorek, KDrozdz, MPodhorska-Okolow, et al. LAM cells biology and lymphangioleiomyomatosis. Folia Histochem Cytobiol 2013;51(1):1-10
   PubMedGoogle Scholar
• DChorianopoulos, GStratakos. Lymphangioleiomyomatosis and tuberous sclerosis complex. Lung 2008;186(4):197-207
   PubMedGoogle Scholar
• SEl-Chemaly, EPHenske. Towards personalised therapy for lymphangioleiomyomatosis: lessons from cancer. Eur Respir Rev 2014;23(131):30-5
   PubMedGoogle Scholar
• ECHarknett, WYCChang, SByrnes, et al. Use of variability in national and regional data to estimate the prevalence of lymphangioleiomyomatosis. QJM 2011;104(11):971-9
   PubMed Web of Science ®Google Scholar
• CBS StatLine - bevolking; kerncijfers [Internet]. Available from: http://statline.cbs.nl/StatWeb/publication/?DM =SLNL&PA=37296ned&D1=a&D2=0,10,20,30,40,50,60,(l-1),l&HDR=G1&STB=T&VW=T [Cited 18 December 2013]
   Google Scholar
• MMCohen, SPollock-BarZiv, SRJohnson. Emerging clinical picture of lymphangioleiomyomatosis. Thorax 2005;60(10):875-9
   PubMed Web of Science ®Google Scholar
• HYPark, HNam, MPChung, et al. A nationwide survey of lymphangioleiomyomatosis in korea: recent increase in newly diagnosed patients. J Korean Med Sci 2010;25(8):1182-6
   PubMedGoogle Scholar
• FXMcCormack. Lymphangioleiomyomatosis. MedGenMed 2006;8(1):15
   PubMedGoogle Scholar
• EAnsotegui Barrera, NMancheno Franch, FVera-Sempere, JPadilla Alarcon. Lymphangioleiomyomatosis. Arch Bronconeumol 2011;47(2):85-93
   PubMedGoogle Scholar
• KFAlmoosa, JHRyu, JMendez, et al. Management of pneumothorax in lymphangioleiomyomatosis: effects on recurrence and lung transplantation complications. Chest 2006;129(5):1274-81
   PubMed Web of Science ®Google Scholar
• YMizushina, MBando, THosono, et al. Clinical features of lymphangioleiomyomatosis complicated by renal angiomyolipomas. Inter Med 2011;50(4):285-9
   PubMedGoogle Scholar
• DMDavies, PJde Vries, SRJohnson, et al. Sirolimus therapy for angiomyolipoma in tuberous sclerosis and sporadic lymphangioleiomyomatosis: a phase 2 trial. Clin Cancer Res 2011;17(12):4071-81
   PubMed Web of Science ®Google Scholar
• LYe, MJin, CBai. Clinical analysis of patients with pulmonary lymphangioleiomyomatosis (PLAM) in mainland china. Respir Med 2010;104(10):1521-6
   PubMedGoogle Scholar
• JTHagaman, DPSchauer, FXMcCormack, BWKinder. Screening for lymphangioleiomyomatosis by high-resolution computed tomography in young, nonsmoking women presenting with spontaneous pneumothorax is cost-effective. Am J Respir Crit Care Med 2010;181(12):1376-82
   PubMedGoogle Scholar
• The Council of the European Union. Council recommendation of 8 june 2009 on an action in the field of rare diseases. Official J Eur Union 2009(151):7-10
   Google Scholar
• THayashi, MVFleming, WGStetler-Stevenson, et al. Immunohistochemical study of matrix metalloproteinases (MMPs) and their tissue inhibitors (TIMPs) in pulmonary lymphangioleiomyomatosis (LAM). Hum Pathol 1997;28(9):1071-8
   PubMed Web of Science ®Google Scholar
• KMatsui, KTakeda, ZXYu, et al. Role for activation of matrix metalloproteinases in the pathogenesis of pulmonary lymphangioleiomyomatosis. Arch Pathol Lab Med 2000;124(2):267-75
   PubMedGoogle Scholar
• WYChang, JLCane, JDBlakey, et al. Clinical utility of diagnostic guidelines and putative biomarkers in lymphangioleiomyomatosis. Respir Res 2012;13:34
   PubMed Web of Science ®Google Scholar
• SPPimenta, BGBaldi, RAKairalla, CRRCarvalho. Doxycycline use in patients with lymphangioleiomyomatosis: biomarkers and pulmonary function response. J Bras Pneumol 2013;39(1):5-15
   PubMedGoogle Scholar
• WYChang, JLCane, MKumaran, et al. A 2-year randomised placebo-controlled trial of doxycycline for lymphangioleiomyomatosis. Eur Respir J 2014;43(4):1114-23
   PubMed Web of Science ®Google Scholar
• FXMcCormack, YInoue, JMoss, et al. Efficacy and safety of sirolimus in lymphangioleiomyomatosis. N Engl J Med 2011;364(17):1595-606
   PubMed Web of Science ®Google Scholar
• JJBissler, FXMcCormack, LRYoung, et al. Sirolimus for angiomyolipoma in tuberous sclerosis complex or lymphangioleiomyomatosis. N Engl J Med 2008;358(2):140-51
   PubMed Web of Science ®Google Scholar
• XCai, GPacheco-Rodriguez, MHaughey, et al. Sirolimus decreases circulating lymphangioleiomyomatosis cells in patients with lymphangioleiomyomatosis. Chest 2014;145(1):108-12
   PubMed Web of Science ®Google Scholar
• JJBissler, JCKingswood, ERadzikowska, et al. Everolimus for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis (EXIST-2): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet 2013;381(9869):817-24
   PubMed Web of Science ®Google Scholar
• LRYoung, HLee, YInoue, et al. Serum VEGF-D concentration as a biomarker of lymphangioleiomyomatosis severity and treatment response: a prospective analysis of the multicenter international lymphangioleiomyomatosis efficacy of sirolimus (MILES) trial. Lancet Respir Med 2013;1(6):445-52
   PubMed Web of Science ®Google Scholar